Table 3. Effects of Moderators on Each Outcome.
| Variables | IPSS | QoL value | Qmax | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| k | Coef.* | SMD | SE | 95% CI | p value† | p value‡ | k | Coef.* | SMD | SE | 95% CI | p value† | p value‡ | k | Coef.* | SMD | SE | 95% CI | p value† | p value‡ | ||||
| Number of patients | 10 | 0.001 | - | 0.001 | -0.002 | 0.004 | - | 0.392 | 7 | 0.001 | - | 0.002 | -0.003 | 0.006 | - | 0.459 | 10 | 0.001 | - | 0.001 | -0.001 | 0.003 | - | 0.247 |
| Study duration (wks) |
10 | -0.008 | - | 0.037 | -0.094 | 0.078 | - | 0.832 | 7 | -0.040 | - | 0.065 | -0.208 | 0.128 | - | 0.568 | 10 | 0.029 | - | 0.025 | -0.027 | 0.086 | - | 0.265 |
| Country | 0.444 | - | 0.074 | - | 0.369 | |||||||||||||||||||
| Japan | 5 | - | -0.094 | 0.183 | -0.453 | 0.264 | 5 | - | -0.010 | 0.178 | -0.358 | 0.338 | 5 | - | 0.060 | 0.120 | -0.175 | 0.295 | ||||||
| China | 4 | - | 0.111 | 0.196 | 0.274 | 0.496 | 2 | - | 0.559 | 0.265 | 0.040 | 1.077 | 4 | - | -0.095 | 0.124 | -0.339 | 0.148 | ||||||
| Control agent | - | 0.061 | - | - | 0.193 | - | 0.127 | |||||||||||||||||
| Naftopidil | 4 | - | -0.252 | 0.129 | -0.505 | 0.001 | 3 | - | -0.110 | 0.170 | -0.443 | 0.223 | 4 | - | -0.051 | 0.104 | -0.256 | 0.154 | ||||||
| Terazosin | 3 | - | -0.039 | 0.143 | -0.320 | 0.242 | 3 | - | 0.059 | 0.110 | -0.155 | 0.274 | ||||||||||||
| Silodosin | 2 | - | 0.193 | 0.137 | -0.075 | 0.461 | 2 | - | 0.204 | 0.171 | -0.131 | 0.538 | 2 | - | 0.219 | 0.086 | 0.050 | 0.389 | ||||||
SMD, standardized mean difference (Hedges's g); k, number of effect sizes; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, maximal urinary flow rate; SE, standard error; CI, confidence interval.
*Regression coefficient, †p values from meta-ANOVA for categorical moderators, ‡p values from random effect meta-regression using restricted maximum likelihood for countinuous moderators.